Next Gen Immuno-Oncology UK 2022


Maik Pruess

Maik Pruess, PhD
Senior Field Application Scientist
Personalis, Inc.

March 11, 2022 | 11:00 AM GMT

Personalis NeXT Platform

Enabling the future of precision oncology with comprehensive, unprecedented tumor profiling solutions for both tissue and liquid biopsy

  • Combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXTTM provides a multidimensional view of the tumor and the tumor microenvironment from a single tumor sample preparation
  • A clinical case study in a cohort of late-stage melanoma patients demonstrating how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers
  • In parallel, specimens may be processed using NeXT PersonalTM, an ultrasensitive tumor-informed liquid biopsy assay, designed to detect molecular residual disease and cancer recurrence at the earliest timepoints, with simultaneous variant tracking for additional insight into disease progression

Connect with us at Next Gen Immuno-Oncology Congress UK 2022